CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years&lt;subtitle&gt;The Swiss HIV Cohort Study&lt;/subtitle&gt;

Kaufmann, Gilbert R.; Perrin, Luc; Pantaleo, G.; Opravil, Milos; Furrer, Hansjakob; Telenti, Amalio; Hirschel, Bernard; Ledergerber, Bruno; Vernazza, Pietro; Bernasconi, Enos; Rickenbach, Martin; Egger, Matthias; Battegay, Manuel

doi:10.1001/archinte.163.18.2187

Cited by 366 publications

(324 citation statements)

References 33 publications

Supporting

Mentioning

264

Contrasting

Unclassified

Order By: Relevance

“…12,13 Previous studies have found that impaired IL-7 responsiveness is significantly associated with poor CD4 T-cell recovery following cART. 14,15 Various clinical factors have been associated with impaired CD4 T-cell reconstitution following cART, including lower CD4 T-cell counts at initiation of cART, [16][17][18][19] being older at cART initiation 1,17,19,20 and higher levels of immune activation both before and while on cART as measured by T-cell activation markers (such as human leukocyte antigen (HLA)-DR þ CD38 þ expression). [21][22][23][24] Multiple host genetic factors have also been found to influence CD4 T-cell recovery.…”

Section: Introductionmentioning

confidence: 99%

The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART

et al. 2011

View full text Add to dashboard Cite

We previously found an association between faster CD4 þ T-cell recovery in HIV-infected patients receiving combination antiretroviral therapy (cART) and interleukin-7 receptor-a (IL-7Ra) haplotype-2 in a predominantly Caucasian cohort. This study aims to determine whether this association was also significant in Africans. Patients were recruited from the Uganda AIDS Rural Treatment Outcomes (UARTO) cohort (n ¼ 352). We used survival analysis and linear mixed modelling (LMM) to determine factors associated with CD4 T-cell recovery. Eight IL-7Ra single-nucleotide polymorphisms (SNPs) were genotyped in both Africans and Caucasians (n ¼ 57). Soluble (s)IL-7Ra levels were measured by ELISA. In UARTO, IL-7Ra haplotype-2 was associated with slower CD4 T-cell recovery following cART by using survival analysis (P ¼ 0.020) and no association was found with LMM (P ¼ 0.958). The tagging-SNP for IL-7Ra haplotype-2 (rs6897932) was associated with decreased sIL-7Ra (Po0.001). The haplotypes for the IL-7Ra were significantly different in Africans and Caucasians. Using IL-7Ra genotypes we found slower CD4 T-cell recovery in UARTO patients was still associated with rs6897932 (P ¼ 0.009) and rs3194051 was associated with faster CD4 T-cell recovery (P ¼ 0.006). Unlike Caucasians, we did not demonstrate a significant association between IL-7Ra haplotype 2 and faster CD4 T-cell recovery in Africans. The IL-7Ra SNPs associated with CD4 T-cell recovery following cART differ in African and Caucasian cohorts.

show abstract

Section: Introductionmentioning

confidence: 99%

The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In fact, some studies with longer follow-up periods have established that slight increases continue for about 2 years, reaching a plateau thereafter [2,4,21,22]. Other studies that also reported the response of CD4 count to HAART found increases of 180-201 cells/mL at 48 weeks in patients treated with diverse antiretroviral regimens [23], 200 cells/mL in naïve patients at 48 weeks [24], 126-187 cells/mL at 48 weeks in patients at various disease stages [5], 143 cells/mL at 72 weeks in patients starting indinavir-containing regimens [22], 186-280 cells/mL in naïve patients at 96 weeks depending on different baseline strata of CD4 [4], 190-423 cells/mL at 48 months in patients on continuous and discontinuous HAART [10], and 299 cells/mL at 48 months in naïve and experienced patients, with higher final absolute values for the less advanced clinical stages [2].…”

Section: Discussionmentioning

confidence: 99%

“…Suppression of viral load as a result of HAART has been found to be in the range 37-91% depending on various factors such as prior experience with HAART, initial CD4 cell count and viral load, length of the follow-up period, type of analysis and threshold used for undetectability [3][4][5][6][7]10,23,24,[30][31][32][33][34][35]. Although some authors did not find differences in viral responses depending on history of prior antiretroviral treatment [30], most studies [7,25,35] confirm our finding of greater virological responses to HAART in naïve than in experienced patients.…”

Section: Discussionmentioning

confidence: 99%

“…All forms were sent to a single institution for data to be transferred to a computer database. Patients were evaluated at baseline and at the 3rd, 6th and 12th months after starting NFV therapy [mean deviations 1 10.5 (95% confidence interval (CI) 9-12), [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] and [1][2][3][4][5][6], respectively]. A large amount of sociodemographic, clinical and laboratory data, including CD4 cell count and viral load, was recorded for each patient.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

CD4 count and viral load time‐courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system

et al. 2006

View full text Add to dashboard Cite

ObjectivesThe aim of the study was to analyse CD4 cell count and viral load dynamics in patients undergoing antiretroviral therapy and their association with the Centers for Disease Control and Prevention (CDC) classification system. MethodsCD4 cell count and viral load were determined in 2982 patients who were classified according to clinical and immunological CDC stages. Measurements were carried out at baseline and at the 3rd, 6th and 12th months. ResultsClear differences in the immunological and virological responses to therapy were observed depending on the CDC stage, with better results associated with less advanced stages. There was a marked parallelism in the CD4 cell count curves of the different CDC stages over the year of follow up, in both naïve and experienced patients, indicating that the increase in CD4 cell count at each time-point was similar for all clinical and immunological CDC stages. However, as the baseline values were closely associated with CDC stage, the CD4 cell counts finally reached were clearly dependent on CDC stage. The highest virological responses were observed during the initial 3 months, particularly in naïve patients, but whereas naïve patients showed additional increases up to the 6th month experienced patients reached a plateau at the 3rd month. The CD4 increases were also higher during the initial 3 months but persisted during the year of follow-up. ConclusionBoth clinical and immunological CDC stages at baseline are highly predictive of the immunological and virological response to therapy, a finding that could have clinical implications.

show abstract

“…Today, antiretroviral (ARV) therapy is potent, convenient/simple or easy and usually well tolerated, and causes capable of reducing HIV blood concentration to undetectable values within a few weeks from therapy initiation and of inducing a robust and sustained CD4 T-cell gain. 1,2 The introduction of HIV protease inhibitors (PIs) in 1995 and the application of highly active anti-retroviral therapy (HAART), i.e. combination of PI with other antiretrovirals, mainly inhibitors of the HIV reverse transcriptase, increased the life expectancy of of HIV-positive patients .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Rumex Vesicarius Linn and Symplocos Racemosa Roxb as Probable Hiv-Protease Inhibitors

Manure¹,

Naikwade²

2017

Int. Res. J. Pharm.

View full text Add to dashboard Cite

The objective of the present study to evaluate in-vitro antiviral activity of different extracts of leaves of Rumex vesicarius Linn and Symplocos racemosa Roxb. In this study in-vitro antiviral activity was assayed by pepsin. Pepsin was used as a substitute for HIV-protease to evaluate inhibitory activity of these plants, as pepsin has close resemblance with HIV-protease in proteolytic activity. We have evaluated antiviral activity of different extracts of leaves of Rumex vesicarius Linn and Symplocos racemosa Roxb. But neither different extract of leaves of Rumex vesicarius Linn shows antiviral activity or protease inhibitory activity nor different extract of leaves of Symplocos racemosa Roxb. We have used pepstatin A as a standard (Positive control) which is a natural inhibitor of pepsin enzyme. The study demonstrated that the different extracts of Rumex vesicarius Linn and Symplocos racemosa Roxb did not show antiviral activity or protease inhibitory activity.

show abstract

CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years<subtitle>The Swiss HIV Cohort Study</subtitle>

Cited by 366 publications

References 33 publications

The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART

The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART

CD4 count and viral load time‐courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system

Evaluation of Rumex Vesicarius Linn and Symplocos Racemosa Roxb as Probable Hiv-Protease Inhibitors

Contact Info

Product

Resources

About